3C-DFM, also known as 4-(2,2-difluoromethoxy)-3,5-dimethoxyamphetamine or as or as ñ-methyldifluoromescaline (3C-difluoromescaline), is a serotonin receptor modulator of the phenethylamine and 3C families. It is the amphetamine (ñ-methyl) derivative of the psychedelic drug difluoromescaline (DFM). The properties and effects of 3C-DFM in humans are unknown. The drug shows affinity for the serotonin 5-HT<sub>2</sub> receptors and is known to act as an agonist of the serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors. 3C-DFM was first described in the scientific literature by Daniel Trachsel by 2012. It is a controlled substance in Ukraine. The drug is also a controlled substance in Canada under phenethylamine blanket-ban language.